fda glp-1 warning news november 2025 The New York Times spotlighted MEDVi. The had already warned the self-proclaimed 'fastest growing company in history.' The U.S. health regulator asked

Adjusting Your Dosage For some patients, it may be appropriate to increase the GLP-1 dosage, especially for those who are closer to the beginning of their treatment

Self-administering unregulated injectable substances carries serious risks, including infection, embolism, and systemic toxicity

Omvohwhich is the second new treatment option for UC patients approved this week after Celltrions Zymfentrais the first to selectively target the p19 subunit of IL-23, which plays a role in inflammation related to the condition, according to Lilly

Proton pump inhibitors (PPIs) such as omeprazole or esomeprazole represent the most effective option for managing persistent reflux symptoms

Third, major obstacles persist for clinical translation